• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Combination treatment with varenicline and nicotine patch improves smoking cessation outcomes for concurrent alcohol users

byZoya GomesandMichael Pratte
April 7, 2022
in Chronic Disease, Psychiatry, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this randomized controlled trial, combined treatment with varenicline and nicotine patch produced higher smoking cessation rates versus nicotine patch with placebo over a 12-week period for 122 participants who concurrently consumed alcohol in excess.

2. There was no significant difference in reduction of alcohol consumption in the varenicline group versus placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Concurrent use of both tobacco and alcohol results in higher rates of cancer, pulmonary and cardiovascular disease, and an overall increase in mortality risk. Although combined treatment with varenicline and nicotine patches are known to be an a highly effective pharmacotherapy approved for smoking cessation, the treatment’s effects have not been examined among smokers who drink heavily. This randomized controlled trial investigated the combined treatment of varenicline and nicotine patch on smoking cessation rates over 9-12 weeks in smokers who drank heavily (defined as an Alcohol Use Disorders Identification Test score greater or equal to 8). The primary outcome for this study was self-reported continuous cigarette abstinence over 12 weeks. Secondary outcomes included the frequency of weekly drinking, and heavy drinking during the study period. Among the 122 participants (mean age, 44.0 [12.4] years; 61 men [54.9%]), the varenicline group consisted of 61 participants randomly assigned to receive a combined treatment (varenicline and nicotine patch), and the placebo group consisted of 61 participants randomly assigned to receive a placebo and nicotine patch. Smoking cessation rates were higher for participants in the varenicline group receiving combined treatment in comparison to the placebo group. Frequency of heavy drinking and any alcohol drinking were decreased by 54% over 12 weeks amongst both groups, without significant difference in decrease in either arm. These results suggest that there is potential for smokers who drink heavily to be enrolled and retain in a smoking cessation treatment program. A limitation to this study is the smaller sample size, which precludes the analyses of moderators of varenicline’s effects, such as sex and race.

Click to read the study in JAMA Network Open

Relevant Reading: Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation

In-Depth [randomized controlled trial]: This study included 122 participants that were randomized to receive either varenicline and nicotine patch (n=61), or placebo (n=61) and investigated smoking cessation rates in smokers who drink heavily. Smoking cessation rates were higher in the varenicline group in comparison to the placebo group during the 9 to 12 weeks (OR, 2.20; 95% CI, 1.01-4.80; P=.047). The combination treatment resulted in a quit rate of 44.3%. A lower likelihood of relapse for patients with continuous cigarette use was confirmed in those in the varenicline group (HR, 0.62; 95% CI, 0.40-0.96, P=.03). Participants were enrolled in the study independent of their desire to change their alcohol consumption patterns, however both groups saw a decrease in weekly drinking days by 25% (P = .003) and weekly heavy drinking days decreased by 54% (P = .004); difference in this outcome was nonsignificant (P = .81). Additionally, participants in the combined treatment group experienced significantly more frequent nausea (34 participants; P = .003). Adverse events were rated as mild or moderate among both groups.

RELATED REPORTS

Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

Unhealthy alcohol use may be common amongst patients in the emergency department

Wellness Check: Addictions

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Alcoholcigarettecigarette smokingsmokingsmoking cessationvarenicline
Previous Post

#VisualAbstract: Peanut oral immunotherapy desensitizes young children with non-anaphylactic peanut allergies

Next Post

#VisualAbstract: Stage-specific and time-specific recurrence data can help determine need for surveillance in Merkel cell carcinoma patients

RelatedReports

Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery
Chronic Disease

Segmentectomy is superior to lobectomy for patients with early-stage non-small cell lung cancer

May 3, 2022
Greater prenatal alcohol exposure trajectories linked to impaired growth and neurodevelopment
Wellness

Unhealthy alcohol use may be common amongst patients in the emergency department

February 7, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Wellness

Wellness Check: Addictions

February 3, 2022
Greater prenatal alcohol exposure trajectories linked to impaired growth and neurodevelopment
Chronic Disease

Online mutual help for alcohol use recovery may have decreased during COVID-19 pandemic

December 29, 2021
Next Post
#VisualAbstract: Stage-specific and time-specific recurrence data can help determine need for surveillance in Merkel cell carcinoma patients

#VisualAbstract: Stage-specific and time-specific recurrence data can help determine need for surveillance in Merkel cell carcinoma patients

Dietary variety linked to greater increase in childhood BMI

Pro-inflammatory diets may objectively negatively impact sleep amongst police officers

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors

2 Minute Medicine Rewind March 14, 2022

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
  • #VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.